GSDMD and bronchiectasis: Moreover, because the current GSDMD-targeting agents fail to effectively block GSDMD activation in patient-derived neutrophils, whether GSDMD constitutes a viable therapeutic target for controlling NETosis in bronchiectasis warrants further investigation.